Development of an immunoassay for serum caveolin-1: A novel biomarker for prostate cancer

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3653-3659

  Tahir, Salahaldin A ^a   Ren, Chengzhen ^a   Timme, Terry L ^a   Gdor, Yehoshua ^a   Hoogeveen, Ron ^a   Morrisett, Joel D ^a   Frolov, Anna ^a   Ayala, Gustavo ^a   Wheeler, Thomas M ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CAVEOLA; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; ANIMALS; ANTIBODIES; BLOTTING, WESTERN; CALIBRATION; CAVEOLIN 1; CAVEOLINS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RABBITS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 12444333159     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA - Cancer J. Clin., 51: 15-36, 2001.
2. Brawley, O. W., Giovannucci, E., and Kramer, B. S. Epidemiology of prostate cancer. In: S. P. Vogelzang, W. U. Shipley, and D. S. Coffey (eds.), Comprehensive Textbook of Genitourinary Oncology, pp. 533-544. Philadelphia, PA: Lippincott Williams and Wilkins, 2000.
3. Stephan, C., Jung, K., Diamandis, E. P., Rittenhouse, H. G., Lein, M., and Loening, S. A. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology, 59: 2-8, 2002.
4. Babaian, R. J., Camps, J. L., Frangos, D. N., Ramirez, E. I., Tenney, D. M., Hassell, J. S., and Fritsche, H. A. Monoclonal prostate-specific antigen in untreated prostate cancer. Relationship to clinical stage and grade. Cancer (Phila.), 67: 2200-2206, 1991.
5. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., and Walsh, P. C. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
6. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C., and Scardino, P. T. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol., 152: 1843-1849, 1994.
7. Zietman, A. L., Edelstein, R. A., Coen, J. J., Babayan, R. K., and Krane, R. J. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828-833, 1994.
8. Li, W. P., Liu, P., Pilcher, B. K., and Anderson, R. G. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J. Cell Sci., 114: 1397-1408, 2001.
9. Yang, G., Truong, L. D., Timme, T. L., Ren, C., Wheeler, T. M., Park, S. H., Nasu, Y., Bangma, C. H., Kattan, M. W., Scardino, P. T., and Thompson, T. C. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res., 4: 1873-1880, 1998.
10. Yang, G., Truong, L. D., Wheeler, T. M., and Thompson, T. C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res., 59: 5719-5723, 1999.
11. Yang, G., Addai, J., Ittmann, M., Wheeler, T. M., and Thompson, T. C. Elevated caveolin-1 levels in African-American versus white American prostate cancer. Clin. Cancer Res., 6: 3430-3433, 2000.
12. Nasu, Y., Timme, T. L., Yang, G., Bangma, C. H., Li, L., Ren, C., Park, S. H., DeLeon, M., Wang, J., and Thompson, T. C. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med., 4: 1062-1064, 1998.
13. Tahir, S. A., Yang, G., Ebara, S., Timme, T. L., Satoh, T., Li, L., Goltsov, A., Ittmann, M., Morrisett, J. D., and Thompson, T. C. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res., 61: 3882-3885, 2001.
14. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
15. Redgrave, T. G., Roberts, D. C., and West, C. E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem., 65: 42-49, 1975.
16. Crowther, J. R. The ELISA guidebook. In: Methods in Molecular Biology, Vol. 149, pp. 83-115. Totowa, NJ: Humana Press, 2001.
17. Li, L., Yang, G., Ebara, S., Satoh, T., Nasu, Y., Timme, T. L., Ren, C., Wang, J., Tahir, S. A., and Thompson, T. C. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res., 61: 4386-4392, 2001.
18. Timme, T. L., Goltsov, A., Tahir, S., Li, L., Wang, J., Ren, C., Johnston, R. N., and Thompson, T. C. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene, 19: 3256-3265, 2000.
19. Fidler, I. J. Critical factors in the biology of human cancer metastasis: 28th G. H. A. Clowes Memorial Award Lecture. Cancer Res., 50: 6130-6138, 1990.
20. Liu, P., Li, W. P., Machleidt, T., and Anderson, R. G. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat. Cell Biol., 1: 369-375, 1999.
21. Fielding, C. J., and Fielding, P. E. Intracellular cholesterol transport. J. Lipid Res., 38: 1503-1521, 1997.
22. Wu, J. T. Assay for prostate specific antigen (PSA): problems and possible solutions. J. Clin. Lab. Anal., 8: 51-62, 1994.